-
Mashup Score: 3
If approved by the FDA, it would be only the second drug available to treat transthyretin amyloid cardiomyopathy.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
If approved by the FDA, it would be only the second drug available to treat transthyretin amyloid cardiomyopathy.
Source: TCTMD.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ATTRibute-CM Top-Line Results Favorable for Acoramidis in Transthyretin Amyloidosis https://t.co/uTwNoAjGM9 https://t.co/L7T16VUtZy
-
-
Mashup Score: 0Vaping’s Risks to CV Health Not Yet Fully Known: AHA - 1 year(s) ago
A new scientific statement outlines potential acute and chronic effects, regulatory and public health efforts, and knowledge gaps
Source: TCTMD.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Vaping’s Risks to CV Health Not Yet Fully Known: AHA https://t.co/jUIWfnJB8O https://t.co/zADTcUOoBx
-
-
Mashup Score: 0SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients - 1 year(s) ago
The observational results are hypothesis-generating, but more-definitive randomized trial data are coming soon.
Source: TCTMD.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients https://t.co/h8tHMwkotU https://t.co/bo7zoiZ0ya
-
-
Mashup Score: 1
Cleveland Clinic data, amid ongoing RCTs, suggest ways to target those with moderate AS most likely to benefit from earlier AVR.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
For Moderate AS Patients, Baseline Factors Can Help ID Who’s Most at Risk New Cleveland Clinic study reveals nearly 50% of moderate aortic stenosis (AS) patients experience a major cardiovascular event within a year of diagnosis. @TCTMD https://t.co/ZLTlXxiwFT
-
-
Mashup Score: 0
These patients were less likely to receive standard care for acute coronary syndrome, which may explain the greater risk.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
Important work. As Dr Qamar is always quick to point out, in #Medicine , it’s always better to collaborate than to compete! #CardioTwitter https://t.co/8Q7ebpSVoV
-
-
Mashup Score: 3
Frustration over MOC is nothing new, but alternative certification options and a fresh, post-COVID perspective are fueling the fire.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @InfoNbpas: Great article! Thank you @ToddNeale @Allison_Dupont @doctorwes and @TCTMD https://t.co/zSM28iSndp
-
-
Mashup Score: 3
Frustration over MOC is nothing new, but alternative certification options and a fresh, post-COVID perspective are fueling the fire.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
“Other complaints abound. Some point to the ABIM’s sharing and selling of physician data, particularly in light of a recent data breach affecting about 800 organizations, including the ABIM.” https://t.co/S1Ld7smDNp
-
-
Mashup Score: 1
Frustration over MOC is nothing new, but alternative certification options and a fresh, post-COVID perspective are fueling the fire.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
“@ABIMFoundation: What is it good for (certainly not maintenance of competency)?”… @TCTMD @InfoNbpas https://t.co/T48j1Ge5Ub
-
-
Mashup Score: 0TCTMD - tctmd.com - 1 year(s) ago
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
Cardiologists’ Anger Flares Anew Over ABIM Maintenance of Certification | https://t.co/aIrzy0yu3t https://t.co/RR9xRYUbFW
-
RT @TCTMD: ATTRibute-CM Top-Line Results Favorable for Acoramidis in Transthyretin Amyloidosis https://t.co/uTwNoAjGM9 https://t.co/L7T16VU…